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Background/Aims: Dietary supplementation with 2.0-2.5 g per day of
phytosterols (PS) is well known to reduce LDL cholesterol levels by 10-15%.
The most common form of PS-enriched food products are the fat
(margarine) spreads. The predominant fat used in these spreads is either
soybean/sunﬂower (SS) or rapeseed/canola (RC) oils. This study aimed to
investigate whether the carrier fat is a determinant of the hypo-
cholesterolaemic effects of PS-enriched spreads.
Methods: Four databases (Medline, Cochrane, Embase, CINAHL) were
searched using relevant search terms. Published RCTs from 1990 investi-
gating the effects of dietary PS intervention ( 1.5 g per day) on plasma
total (TC) and LDL cholesterol were included. Duplicates (n ¼ 1177) were
removed. Methodological quality of articles was assessed by two inde-
pendent researchers using the Academy of Nutrition and Dietetics’ Quality
Criteria Checklist. Data extracted using standardised tool (PS dose, dura-
tion, sample size, spread fat type and lipids). Studies grouped by fat type;
meta-analysis conducted.
Results: Of 1484 screened abstracts, a total of 16 RCTs (n¼ 6 SS; n ¼ 10 RC)
were included. 14 studies involved mild to moderate hyper-
cholesterolaemic subjects, and two studies involved normocholester-
olaemic subjects. TC signiﬁcantly reduced by 6% and 8% in SS and RC
studies (respectively; p < 0.05 for both). LDL signiﬁcantly reduced by 8%
and 11% in SS and RC studies (respectively; p < 0.05 for both).
Conclusions: The fat type used for the delivery of PS in fat spreads may be
a determinant of the cholesterol-lowering property of PS.
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Background/Aims: Fat taste sensitivity is impaired in obese individuals
and is associated with consumption of dietary fat. Increasing sensitivity to
fats throughout the alimentary canal may be an effective strategy to ach-
ieve sustainable weight loss. This study assessed the effect of a six-week
low-fat diet or portion control diet matched for weight loss on fat taste
thresholds, fat perception and food preference in overweight or obese
people.
Methods: Participants (n ¼ 53; BMI 31.0 ± 0.7 kg/m2) were randomised to
a six-week low-fat diet (25% total fat) or portion control diet (33% total fat).
Anthropometry, fat taste thresholds (lowest detectable fat concentration),
fat perception (discrimination ability) and preference were assessed at
baseline and week six.
Results: Consumption of a low-fat diet (n ¼ 26) and portion control diet (n
¼ 27) reduced participant’s weight (p < 0.001) with no signiﬁcant differ-
ences between groups. Both diets resulted in a decrease in fat taste
thresholds (increased fat taste sensitivity) (p ¼ 0.014), with a trend for a
stronger effect in the low-fat diet versus the portion control diet (p ¼
0.060). The ability to perceive fat in foods was increased in the low-fat diet
group only (p ¼ 0.017), however preference for the level of fat in foods did
not change.
Conclusions: A low-fat and portion control diet both increased fat taste
sensitivity in overweight or obese people, with the strongest effect in the
low-fat diet group. This increase in fat taste sensitivity may help induce a
healthy satiety response to dietary fat and in turn reduce excess energy
intake and weight gain.
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Background/Aims: Long chain omega-3 poly-unsaturated fatty acids (LCn-
3PUFA) are beneﬁcial for several inﬂammatory conditions. We evaluated
the clinical efﬁcacy of ﬁsh oil supplementation as an adjunct to standard
therapy for advanced chronic periodontitis.
Methods: Participants with advanced chronic periodontitis (10M/23F,
mean age 52 ± 10 years) were randomised to consume ﬁsh oil capsules
providing 1884 mg LCn-3PUFA/day (n ¼ 23) or placebo capsules providing
2000 mg soy oil/day (n ¼ 10) for 4 months in a randomised parallel study
design. Patients were assessed at baseline and after 4 months for clinical
outcomes, viz. probing pocket depth (PPD) and clinical attachment (CAL),
and fasting blood samples were assessed for LCn-3PUFA erythrocyte
content and plasma C reactive protein (CRP). In addition dietary intake of
LCn-3PUFA was assessed using a validated food frequency questionnaire.
Results: Erythrocyte LCn-3PUFA increased by 50% in the ﬁsh oil supple-
mented group with no change in the placebo group. There were no
changes in dietary consumption of LCn-3PUFA in either group indicating
good compliance with supplementation. Both groups had improvements
in clinical outcomes, with signiﬁcant reductions in PPD and CAL gain.
There was no signiﬁcant difference between groups in the percentage of
sites that had  2 mm gain of CAL (p ¼ 0.229) or reduction in PPD (p ¼
0.264) after 4 months and there was no signiﬁcant change in plasma CRP
levels in either group.
Conclusions: Whilst periodontal treatment was effective in all partici-
pants, no additional beneﬁt was observed with ﬁsh oil supplementation
for 4 months.
Funding source(s): Australian Dental Research Foundation grants; Nova-
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Background/Aims: There is a paucity of evidence to guide clinicians about
appropriate nutritional management strategies for obese Chronic
Obstructive Pulmonary Disease (COPD) patients. This study aimed to a)
characterise nutritional biomarkers in obese COPD participants, and b)
evaluate changes in nutritional biomarkers following a weight-loss inter-
vention in obese COPD participants.
Methods: Nutritional biomarkers, plasma fatty acids (FAs) and caroten-
oids, were analysed using GC and HPLC respectively and compared in 10
healthy weight and 39 obese COPD adults. Of the obese COPD participants,
28 completed a weight-loss intervention. Changes in diet quality were
examined using 4-day food records and nutritional biomarkers. Predictors
of weight-loss were examined using multiple linear regression.
Results: Therewas a trend towards higher total plasma FAs (p¼ 0.052) and
carotenoids (p ¼ 0.094) in the obese group. Following the weight-loss
intervention, signiﬁcant decreases in total (p ¼ 0.009) and saturated (p ¼
0.037) fat intake, and corresponding decreases in total (p ¼ 0.007) and
saturated (p ¼ 0.003) plasma FAs were observed. There was a trend to-
wards higher total plasma carotenoids post-intervention (p ¼ 0.078), with
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Older age (p ¼ 0.025), higher pre-intervention uncontrolled eating (p <
0.001) and plasma carotenoids (p ¼ 0.009) predicted weight-loss.
Conclusions: This study provides data which contributes to the charac-
terisation of nutritional biomarkers in obese COPD patients. We have also
demonstrated the efﬁcacy of a weight-loss intervention in improving diet
quality in this population. Future studies are needed to conﬁrm these
ﬁndings, and examine the long-term efﬁcacy of the weight-loss
intervention.
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Background/Aims: Improved ﬂow mediated dilatation (FMD) has been
reported in some but not all weight loss studies. Restricting sodium is
known to improve FMD. It is unclear whether weight loss combined with
reduced sodium will have a greater beneﬁt on FMD. This study aimed to
determine the effects of weight loss and reduced sodium intake on FMD.
Methods: Participants were randomly assigned to two groups, in a parallel
design. All participants reduced sodium intake by 50 mmol for one week.
Group 1 (weight loss) then used low sodiummeal replacements for weight
loss, and Group 2 (control, no weight loss) continued their usual diet for 8
weeks. Adherence was assessed using 24 hr urinary sodium excretion.
FMD, blood pressure (BP), and 24 hr urinalysis were measured at baseline
and at completion of each intervention phase.
Results: Twenty-ﬁve participants (14 women; BMI: 34.7 ± 5.9 kg/m2; age:
42 ± 16 y) were enrolled and 23 participants completed the protocol. FMD
(2.3 ± 1.1%, p ¼ 0.04, n ¼ 25) and DBP (-2.7 ± 10mmHg, p ¼ 0.01, n ¼ 25)
improved after the sodium reduction. During the weight loss phase, mean
weight changewas -3.0 ± 3.3 kg Group 1 (n¼ 13) and +1.1 ± 1.2 kg Group 2
(n¼ 10), p¼ 0.02. There were no between group differences in FMD during
the weight loss phase. Urinary sodium decreased in Group 1 (-87 ± 18
mmol/d, p < 0.01) and Group 2 (-95 ± 25 mmol/d, p < 0.01) during sodium
restriction, and remained lower (Group 1: -67 ± 20 mmol/d, p ¼ 0.01;
Group 2: -69 ± 24 mmol/d, p ¼ 0.02) during the weight loss phase.
Conclusions: These results suggest reducing sodium intake improves FMD
but the combination of modest weight loss does not provide additional
beneﬁt.
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Background/Aims: Patients suffering from the inﬂammatory disorder ul-
cerative colitis (UC) have an increased risk of developing colorectal cancer
(CRC). Previously, we demonstrated that Emu Oil (EO) reduced inﬂam-
mation and protected the intestine against UC, NSAID-enteropathy and
chemotherapy-inducedmucositis. We aimed to determine whether orally-
administered EO could reduce the severity of inﬂammation-associated CRC
in mice.
Methods:Mice (n¼ 8 per group) were orally-administered either water or
EO (EO1: 80 mL or EO2: 160 mL), thrice weekly. Mice were injected with
azoxymethane (AOM), followed by 3 cycles each consisting of 7 days
dextran sulphate sodium (DSS) and 14 days drinking water; and culled 3
weeks after the last cycle. Bodyweights, organ data and colonic tumour
numbers were recorded. P < 0.05 was considered signiﬁcant.
Results: During the ﬁrst 2 DSS-weeks, AOM/DSS decreased bodyweightgain compared to normal controls (maximum 23%; p < 0.05). However, in
AOM/DSS mice, EO2 increased bodyweight gain compared to untreated
and EO1-treated mice (maximum 10%; p < 0.05) during the 3rd DSS-week
until cull. Spleen weight was greater in AOM/DSS-treated mice (water: 0.3
± 0.03%; EO1: 0.3 ± 0.05%; EO2: 0.3 ± 0.03% relative to bodyweight)
compared to normal controls (0.2 ± 0.05%; p < 0.05). Thymus weight
decreased only in AOM/DSS control mice, compared to normal controls (p
< 0.05). AOM/DSS resulted in CRC development (water: 10.1 ± 1.7; EO1:
10.3 ± 1.2; EO2: 9.4 ± 1.7 tumour count) compared to normal controls (0 ±
0; p < 0.05).
Conclusions: Despite improved bodyweight, emu oil did not decrease the
number of colonic tumours. Further studies underway include assess-
ments of tumour size, histological morphometry, apoptosis and prolifer-
ation and pro-inﬂammatory cytokines.
Funding source(s): Cancer Council of Western Australia.
EFFECT OF COMBINED FISH OIL PLUS COENZYME Q10
SUPPLEMENTATION ON OMEGA-3 INDEX AND CARDIOVASCULAR RISK
MARKERS IN OVERWEIGHT MEN
H. Parker 1,2, H. O'Connor 1,2, J. Cohn 3, M. Garg 4, I. Caterson 5, J. George 6, N.
Johnson 1,2. 1 Faculty of Health Science, University of Sydney (USyd),
Australia; 2Charles Perkins Centre, USyd, Australia; 3Heart Research
Institute, Sydney, Australia; 4 School of Biomedical Sciences & Pharmacy,
University of Newcastle, Australia; 5Boden Institute (BIONE), USyd,
Australia; 6 Storr Liver Unit, Westmead Millennium Institute, USyd, Australia
E-mail address: hcoo0650@uni.sydney.edu.au (H. O'Connor)
Background/Aims: A high Omega-3 Index is associated with a lower risk
of sudden cardiac death, and dietary ﬁsh oil supplementation has been
shown to improve cardiovascular disease (CVD) risk factors. There is little
research examining CVD risk factor modiﬁcation resulting from change in
the Omega-3 Index due to ﬁsh oil supplementation. We aimed to assess
the effects of 12 weeks ﬁsh oil supplementation on change in Omega-3
Index together with CVD risk factors.
Methods: Fifty overweight men were randomised to receive ﬁsh oil (1728
mg ﬁsh oil containing 1000mg EPA + DHA per day) combined with 200mg
antioxidant (coenzyme Q10), or placebo (2 g olive oil) for 12 weeks.
Anthropometry and biochemical outcomes were measured at baseline, six
and 12 weeks supplementation. Relationships between change in Omega-
3 Index and change in anthropometric and biochemical outcomes were
examined by linear regression.
Results: Forty-eight men completed the trial. Baseline Omega-3 Index was
high in both the ﬁsh oil and placebo groups (7.9 ± 0.4% and 8.1 ± 0.3%,
respectively). Fish oil supplementation resulted in a large and signiﬁcant
increase in Omega-3 Index (D 2.8 ± 0.3%), whereas placebo supplemen-
tation did not (D 0.3 ± 0.2%, p < 0.001). There was no signiﬁcant effect of
change in Omega-3 Index on CVD risk markers (p > 0.05 for all).
Conclusions: In overweight menwith a high baseline Omega-3 Index ﬁsh,
oil supplementation increased the Omega-3 Index but this was not asso-
ciated with improvement in CVD risk markers.
Funding source(s): Blackmores Australia Ltd.
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Background/Aims: Adipokines, such as resistin and adiponectin, may
contribute to increased asthma risk and severity in obese people. We
aimed to examine plasma resistin and resistin:adiponectin ratio in asth-
matics compared to healthy controls, according to asthma severity, BMI
and gender, following weight loss in obese asthmatics.
Methods: In a cross-sectional observational study of asthmatic adults (n ¼
96) and healthy controls (n ¼ 46), plasma resistin and adiponectin were
measured. In a separate intervention study, obese asthmatic adults (n ¼
27) completed a 10-weekweight-loss intervention and plasma resistin and
adiponectin were measured.
